Organigram Global (NASDAQ:OGI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Organigram Global (NASDAQ:OGI) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Organigram Global in a report on Tuesday, June 9th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Organigram Global Trading Down 0.4%

NASDAQ:OGI opened at $1.23 on Friday. The company has a market cap of $172.70 million, a P/E ratio of 2.66 and a beta of 1.46. Organigram Global has a twelve month low of $0.85 and a twelve month high of $2.24. The business has a 50 day moving average price of $1.00 and a two-hundred day moving average price of $1.23. The company has a quick ratio of 1.07, a current ratio of 2.61 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Lazard Asset Management LLC increased its position in shares of Organigram Global by 108.3% during the 1st quarter. Lazard Asset Management LLC now owns 346,796 shares of the company’s stock worth $465,000 after purchasing an additional 180,327 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Organigram Global by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 1,640,048 shares of the company’s stock valued at $2,198,000 after buying an additional 234,700 shares during the last quarter. Formidable Asset Management LLC boosted its holdings in shares of Organigram Global by 8.7% in the 1st quarter. Formidable Asset Management LLC now owns 156,749 shares of the company’s stock valued at $210,000 after buying an additional 12,600 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Organigram Global in the fourth quarter valued at $188,000. Finally, Millennium Management LLC bought a new position in shares of Organigram Global in the fourth quarter valued at $1,260,000. 34.63% of the stock is owned by institutional investors and hedge funds.

Organigram Global Company Profile

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.